Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects
Open Access
- 18 April 2013
- journal article
- review article
- Published by Hindawi Limited in Journal of Clinical Pharmacy & Therapeutics
- Vol. 38 (5), 341-349
- https://doi.org/10.1111/jcpt.12067
Abstract
What is known and objective Positive inotropic agents are frequently used in acute decompensated heart failure (ADHF) due to left ventricular systolic dysfunction. These agents are known to improve cardiac performance and peripheral perfusion in the short‐term treatment. However, several preclinical and clinical studies emphasized detrimental effects of these drugs on myocardial oxygen demand and on sympathetic tone entailing arrhythmogenesis. Levosimendan is an inotropic agent with an original mechanism of action. This review focuses on major data available for levosimendan. Methods A literature search was conducted in the PubMed database by including studies published in English using combinations of the following key words, levosimendan, inotropic drugs and acute heart failure. Furthermore, bibliographies of selected references were also evaluated for relevant articles. The collection for this review was limited to the most recently available human and animal data. Results and discussion Levosimendan's vasodilatory and cardioprotective effects are mediated by calcium sensitization of contractile proteins and opening of adenosine triphosphate (ATP)‐dependent K+ channels in vascular smooth muscle cells and on mitochondrial ATP‐sensitive potassium [mito.K(ATP)] channels. This inotropic agent has mild PDE inhibitory action. Unlike other inotropic agents, levosimendan improves cardiac performance without activating the sympathetic nervous system. Moreover, there are evidences that levosimendan has additional anti‐inflammatory and anti‐apoptotic properties that prevent cardiac toxicity and contributes to positive hemodynamic response of the drug. Four randomized trials evaluated the effects of levosimendan on mortality in patients with acute decompensated chronic heart failure; nevertheless, a clear benefit has not been demonstrated so far. Although levosimendan is indicated for the treatment of ADHF (class of recommendation IIa, level of evidence B), it is has not been approved in all countries. What is new and conclusion This review summarizes the characteristics and the current knowledge of the literature on levosimendan and its active metabolite OR‐1896.Keywords
This publication has 90 references indexed in Scilit:
- In vivo and in vitro evidence for pleiotropic effects of levosimendan in the intensive care settingCritical Care, 2011
- A structural and functional perspective into the mechanism of Ca2+-sensitizers that target the cardiac troponin complexJournal of Molecular and Cellular Cardiology, 2010
- Neuroprotective properties of levosimendan in an in vitro model of traumatic brain injuryBMC Neurology, 2010
- Levosimendan vs. dobutamine: outcomes for acute heart failure patients on β‐blockers in SURVIVE†European Journal of Heart Failure, 2009
- Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial KATPchannelBritish Journal of Pharmacology, 2009
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)European Heart Journal, 2008
- Pharmacokinetics of Intravenous Levosimendan and Its Metabolites in Subjects With Hepatic ImpairmentThe Journal of Clinical Pharmacology, 2008
- Dose-dependent effect of dobutamine on chemoreflex activity in healthy volunteersBritish Journal of Clinical Pharmacology, 2006
- The levosimendan metabolite OR‐1896 elicits vasodilation by activating the KATP and BKCa channels in rat isolated arteriolesBritish Journal of Pharmacology, 2006
- Pharmacodynamics and Pharmacokinetics of Oral Levosimendan and Its Metabolites in Patients With Severe Congestive Heart Failure: A Dosing Interval StudyThe Journal of Clinical Pharmacology, 2004